Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Non-Current Assets (2016 - 2025)

Sanofi (SNY) has disclosed Non-Current Assets for 11 consecutive years, with $111.6 billion as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 15.75% to $111.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $111.6 billion through Dec 2025, up 15.75% year-over-year, with the annual reading at $108.3 billion for FY2025, 10.92% up from the prior year.
  • Non-Current Assets hit $111.6 billion in Q4 2025 for Sanofi, up from $96.4 billion in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $111.6 billion in Q4 2025 to a low of $94.5 billion in Q4 2022.
  • Historically, Non-Current Assets has averaged $101.6 billion across 5 years, with a median of $102.5 billion in 2021.
  • Biggest five-year swings in Non-Current Assets: fell 7.81% in 2022 and later rose 15.75% in 2025.
  • Year by year, Non-Current Assets stood at $102.5 billion in 2021, then decreased by 7.81% to $94.5 billion in 2022, then increased by 9.08% to $103.1 billion in 2023, then dropped by 6.47% to $96.4 billion in 2024, then rose by 15.75% to $111.6 billion in 2025.
  • Business Quant data shows Non-Current Assets for SNY at $111.6 billion in Q4 2025, $96.4 billion in Q4 2024, and $103.1 billion in Q4 2023.